The Rationale and Evidence for Radiotherapy in the Management of Gastroesophageal Junction Tumors
Author(s) -
Karin Haustermans
Publication year - 2013
Publication title -
american society of clinical oncology educational book
Language(s) - English
Resource type - Journals
eISSN - 1548-8756
pISSN - 1548-8748
DOI - 10.1200/edbook_am.2013.33.e151
Subject(s) - gastroesophageal junction , medicine , randomized controlled trial , radiation therapy , esophagogastric junction , disease , incidence (geometry) , adenocarcinoma , chemotherapy , clinical trial , meta analysis , esophageal adenocarcinoma , surgery , oncology , cancer , physics , optics
Adenocarcinoma of the gastroesophageal junction (GE-junction) is a frequent disease with a rising incidence. The optimal treatment of localized disease is the subject of many randomized trials and meta-analyses studying the role of preoperative chemotherapy or preoperative chemoradiation compared with surgery alone. A complicating factor in interpreting the results of these trials is the fact that GE-junction tumors are sometimes regarded as esophageal tumors, although in other studies they are regarded as gastric cancers. A thorough review of the literature including meta-analyses clearly indicates that there is a role for preoperative chemoradiation in locally advanced GE-junction tumors. Based on the available evidence a surgery alone arm in future randomized trials for locally advanced GE junction tumors can no longer be regarded as a standard arm.status: publishe
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom